期刊文献+

阿托伐他汀治疗混合型高脂血症40例临床观察

下载PDF
导出
摘要 目的:评价阿托伐他汀治疗混合型高脂血症的疗效和安全性。方法:40例混合型高脂血症患者进入临床观察,每日口服阿托伐他汀10mg,治疗8周。结果:混合型高脂血症患者服用阿托伐他汀10mg,治疗8周,总胆固醇由(7.8±0.9)mmol/L降至(5.6±1.2)mmol/L,LDL-C由(4.5±1.0)mmol/L降至(3.2±1.3)mmol/L,甘油三酯由(3.8±1.1)mmol/L降至(2.6±1.6)mmol/L,治疗前、后差异有统计学意义(P<0.05)。治疗过程中无出现严重不良事件。结论:阿托伐他汀能有效、安全地治疗混合型高脂血症。
出处 《新医学》 北大核心 2003年第z1期20-21,共2页 Journal of New Medicine
  • 相关文献

参考文献5

  • 1[1]Lea AP, Mctavish D. Atorvastatin. A review of its pharmacology and thera peutic potential in the management of hyperlipidemias. Drugs, 1997, 53 (5): 828-847.
  • 2黄震华.新型降脂药物阿托伐他汀[J].中国新药与临床杂志,2000,19(1):54-56. 被引量:29
  • 3柯元南.阿托伐他汀治疗高脂血症的疗效和安全性[J].中华心血管病杂志,2001,29(3):132-135. 被引量:75
  • 4[5]McPherson R, Angus C, Murray P, et al. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women' s Atorvastatin Trial on Cholesterol (WATCH). Am Heart J, 2001, 141 (6): 949-956.
  • 5[6]Bairaktari ET, Tzallas CS, Tsimihodimos VK, et al. Comparison of the ef ficacy of atorvastatin and micron ized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk, 1999, 6 (2): 113-116.

二级参考文献14

  • 1[1]Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia[J]. Drugs 1996; 51: 433-59.
  • 2[2]Naoumova RP, Marais AD, Mountney J, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia[J]. Atherosclerosis 1996; 119: 203-13.
  • 3[3]Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase[J]. Am J Cardiol 1994; 73 Suppl D: 3D-11D.
  • 4[4]Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia[J]. JAMA 1996; 275: 128-33.
  • 5[5]Haria M, McTavish D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease[J]. Drugs 1997; 53: 299-336.
  • 6[6]Bocan TMA, Mazur MJ, Mueller SB, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation[J]. Atherosclerosis 1994; 111: 127-42.
  • 7[7]Lea AP, McTavish D. Atorvastatin, a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias[J]. Drugs 1997; 53: 828-47.
  • 8[8]Heinonen TM, Stein E, Weiss SR, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a double-masked study[J]. Clin Ther 1996; 18: 853-63.
  • 9[9]Naoumova RP, Marais D, Firth JC, Neuwirth CKY, Taylor GW, Thompson GR. Atorvastatin augments therapy of homozygous familial hypercholesterolemia by inhibiting upregulation of cholesterol synthesis after apheresis and bile acid sequestrants[J]. Circulation 1996; 94(8 Suppl): 583.
  • 10[10]Heinonen T, Black D. Atorvastatin monotherapy and combination therapy in the treatment of severe hypercholesterolemia[J]. Atherosclerosis 1995; 115 Suppl: S20.

共引文献101

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部